Harrow, Inc. (NASDAQ:HROW) Receives Consensus Rating of “Moderate Buy” from Analysts

Harrow, Inc. (NASDAQ:HROW) has received an average recommendation of “Moderate Buy” from the ten research firms that are currently covering the stock, Marketbeat reports. Two analysts have rated the stock with a sell rating and eight have issued a buy rating on the company. The average 1 year price objective among brokerages that have issued a report on the stock in the last year is $71.1429.

A number of equities research analysts recently weighed in on the stock. William Blair restated an “outperform” rating on shares of Harrow in a research note on Tuesday, March 3rd. Cantor Fitzgerald lowered their target price on shares of Harrow from $94.00 to $91.00 and set an “overweight” rating on the stock in a research note on Wednesday, March 4th. Weiss Ratings restated a “sell (e+)” rating on shares of Harrow in a research report on Thursday, January 22nd. Zacks Research lowered shares of Harrow from a “hold” rating to a “strong sell” rating in a research note on Tuesday, March 3rd. Finally, HC Wainwright increased their price objective on shares of Harrow from $69.00 to $70.00 and gave the company a “buy” rating in a report on Wednesday, March 4th.

Hedge Funds Weigh In On Harrow

Hedge funds have recently modified their holdings of the company. University of Texas Texas AM Investment Management Co. acquired a new position in shares of Harrow during the 4th quarter valued at $26,000. Raymond James Financial Inc. acquired a new stake in shares of Harrow in the second quarter valued at $48,000. SBI Securities Co. Ltd. boosted its stake in Harrow by 393.5% during the fourth quarter. SBI Securities Co. Ltd. now owns 1,061 shares of the company’s stock valued at $52,000 after buying an additional 846 shares in the last quarter. State of Alaska Department of Revenue acquired a new position in Harrow during the third quarter worth about $83,000. Finally, Mirae Asset Global Investments Co. Ltd. grew its holdings in Harrow by 25.8% during the fourth quarter. Mirae Asset Global Investments Co. Ltd. now owns 1,800 shares of the company’s stock worth $88,000 after acquiring an additional 369 shares during the period. 72.76% of the stock is currently owned by institutional investors and hedge funds.

Harrow Trading Down 4.1%

Shares of HROW stock opened at $34.10 on Friday. Harrow has a 1 year low of $20.85 and a 1 year high of $54.85. The firm has a market capitalization of $1.27 billion, a PE ratio of -200.58 and a beta of 0.05. The stock has a fifty day moving average of $46.23 and a two-hundred day moving average of $43.60. The company has a debt-to-equity ratio of 4.67, a quick ratio of 2.06 and a current ratio of 2.20.

About Harrow

Harrow Health, Inc (NASDAQ: HROW) is a U.S.-based commercial-stage biopharmaceutical company specializing in ophthalmic therapeutics and diagnostics. The company focuses on the development, manufacturing and distribution of proprietary, generic and branded eye care products designed to treat a range of ocular conditions, including glaucoma, ocular hypertension, dry eye disease and other anterior segment disorders.

Through its wholly owned affiliate ImprimisRx, Harrow Health offers a direct-to-physician model for customized formulations as well as low-cost generic alternatives.